Why Is OCULAR THERAPEUTIX I (OCUL) Stock Down Today?

Ocular Therapeutix stock fell 7.24% to $10.64 on Friday as the session unfolded with a steady decline from its opening price. The stock traded as low as $10.62, marking a significant pullback amid a broader market session that saw limited volume. The move followed recent insider selling and a lack of positive catalysts in the company's recent performance.

What Happened

The stock opened at $11.40, slightly below the prior close of $11.47, and quickly moved lower throughout the session. By the end of the day, it had settled at $10.64, a level that represents a new 52-week low. The decline came despite better-than-expected second-quarter results, including earnings per share of -$0.35 and revenue of $13.475 million, both of which exceeded estimates. However, the broader market context and internal factors, including recent insider sales, appear to have weighed on investor sentiment.

What The Data Shows

The stock traded on 1.0 million shares, or 0.4 times its 3-month average daily volume, indicating limited participation. Over the past 30 days, sentiment has averaged 55 out of 100, with a slight improvement to 60 over the last seven days. However, this has not translated into a sustained rally. In the last 90 days, insiders have sold a total of five times, amounting to $333,000 in value. The most recent sale occurred on September 2, 2026. Meanwhile, the stock has hit 37 fresh 52-week lows on September 10, 2026, reflecting ongoing pressure on the price.

What To Watch

The company is currently unprofitable, with a trailing twelve-month earnings per share of -1.41 and revenue declining by 8.1% year to date. Investors should monitor the company’s next earnings report, if scheduled, as well as any further developments in its pipeline or corporate actions that could influence the stock’s direction.